|
|
1.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
2.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
